Zenagamtide

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

ObesityType 2 Diabetes

176 competitors in Obesity

#DrugCompanyPhaseTrials

1

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

12

Retatrutide

Eli Lilly

Phase 3

63

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

44

Berobenatide

Pfizer

Phase 3

55

Cagrisema

Novo Nordisk

Phase 3

56

Naltrexone-Bupropion Combination

CCurrax Pharmaceuticals

Phase 3

27

Zenagamtide

Novo Nordisk

Phase 3

58

Survodutide

Boehringer Ingelheim

Phase 3

29

Semaglutide or Tirzepatide

NNational and Kapodistrian University of Athens

Phase 3

110

Actemra

Roche

Preclinical

2Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity5 trials

An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Semaglutide to Zenagamtide

Recruiting·Novo Nordisk·Phase 1·NCT07855133·60 enrolled

An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Tirzepatide to Zenagamtide

Recruiting·Novo Nordisk·Phase 1·NCT07868354·60 enrolled

Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity (AMAZE 9)

Recruiting·Novo Nordisk·Phase 3·NCT07720271·950 enrolled

Show 2 more trials

Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)

Recruiting·Novo Nordisk·Phase 3·NCT07668414·650 enrolled

Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity (AMAZE 13)

Not yet recruiting·Novo Nordisk·Phase 3·NCT07668401·400 enrolled

Cardiovascular Risk1 trial

Zenagamtide Use for the Reduction of Risk of Major Adverse Cardiovascular Events in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

Not yet recruiting·Novo Nordisk·Phase 3·NCT07861100·8,500 enrolled

Type 2 Diabetes1 trial

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Insulin Glargine s.c. Once Daily in Participants With Type 2 Diabetes and Increased Cardiovascular Risk Inadequately Controlled on 1-3 Oral Glucose-lowering Medications (AMBITION 7)

Recruiting·Novo Nordisk·Phase 3·NCT07797335·1,778 enrolled

Details

Drug Info

Related News